Table 3 Frequency of MC in the ELL-DOPA trial (%)
LD/CD | LD/CD | LD/CD | ||
|---|---|---|---|---|
150 mg | 300 mg | 600 mg | Placebo | |
dyskinesia | 3.3 | 2.3 | 16.5 | 3.3 |
wearing off | 16.3 | 18.2 | 29.7 | 13.3 |
LD/CD | LD/CD | LD/CD | ||
|---|---|---|---|---|
150 mg | 300 mg | 600 mg | Placebo | |
dyskinesia | 3.3 | 2.3 | 16.5 | 3.3 |
wearing off | 16.3 | 18.2 | 29.7 | 13.3 |